Modified polymerases for improved incorporation of nucleotide analogues

ABSTRACT

Presented herein are polymerase enzymes for improved incorporation of nucleotide analogues, in particular nucleotides which are modified at the 3′ sugar hydroxyl, as well as methods and kits using the same.

BACKGROUND

DNA polymerases are relied upon by all organisms to replicate andmaintain their genomes. They allow high fidelity replication of DNA bydetecting complementarity between bases as well as recognizingadditional structural features of the base. There remains a need formodified polymerases with improved incorporation of nucleotideanalogues, in particular nucleotides which are modified at the 3′ sugarhydroxyl.

SEQUENCE LISTING

The present application is being filed along with a Sequence Listing inelectronic format. The Sequence Listing is provided as a file entitledIP1201.TXT, created Sep. 30, 2014, which is 216 Kb in size. Theinformation in the electronic format of the Sequence Listing isincorporated herein by reference in its entirety.

BRIEF SUMMARY

Presented herein are polymerase enzymes for improved incorporation ofnucleotide analogues, in particular nucleotides which are modified atthe 3′ sugar hydroxyl such that the substituent is larger in size thanthe naturally occurring 3′ hydroxyl group. The present inventors havesurprisingly identified certain altered polymerases which exhibitimproved incorporation of the desired analogues and have a number ofother associated advantages.

In certain embodiments, the altered polymerase an amino acid sequencethat is at least 60%, 70%, 80%, 90%. 95%, 99% identical to SEQ ID NO:10, which recombinant DNA polymerase comprises at least one amino acidsubstitution mutation at one or more positions functionally equivalentto Thr144, Gly153, Lys476, Leu478, Thr590, Ala639 or Asp718 in the 9° NDNA polymerase amino acid sequence. The wild type 9° N DNA polymeraseamino acid sequence is set forth in SEQ ID NO: 10.

In certain embodiments, the substitution mutation at position Thr144comprises a mutation to a nonpolar amino acid, for example, a mutationhomologous to Thr144Ala, Thr144Gly, or Thr144Leu. In certainembodiments, the substitution mutation at position Gly153 comprises amutation to a polar amino acid for example, a mutation homologous toGly153Asp. In certain embodiments, the substitution mutation at positionLys476 comprises a mutation to a hydrophobic amino acid, for example, amutation homologous to Lys476Trp. In certain embodiments, thesubstitution mutation at position Leu478 comprises a mutation to a polaramino acid, for example, a mutation homologous to Leu478Ser, Leu478Arg,or Leu478Thr. In certain embodiments, the substitution mutation atposition Thr590 comprises a mutation to a non-polar amino acid, forexample, a mutation homologous to Thr590Ile, or Thr590Gly. In certainembodiments, the substitution mutation at position Ala639 comprises, forexample, a mutation homologous to Ala639Val, or Ala639Phe. In certainembodiments, the substitution mutation at position Asp718 comprises amutation to an uncharged amino acid, for example, a mutation homologousto Asp718Asn.

In some embodiments, the polymerase is a DNA polymerase. For example,the DNA polymerase can be a family B type DNA polymerase. The polymerasecan be, for example, a family B archael DNA polymerase, human DNApolymerase-α, T4, RB69, and phi29 phage DNA polymerases. In certainembodiments, the family B archael DNA polymerase is from a genusselected from the group consisting of Thermococcus, Pyrococcus, andMethanococcus. For example, the polymerase can be selected from thegroup consisting of Vent, Deep Vent, 9° N, and Pfu polymerase. Incertain embodiments, the family B archael DNA polymerase is 9° Npolymerase.

In some embodiments, in addition to the above mutations, the alteredpolymerase can further comprise substitution mutations at positionsfunctionally equivalent to Leu408 and/or Tyr409 and/or Pro410 in the 9°N DNA polymerase amino acid sequence. For example, the substitutionmutations can comprise substitution mutations homologous to Leu408Alaand/or Tyr409Ala and/or Pro410Ile in the 9° N DNA polymerase amino acidsequence.

In some embodiments, the altered polymerase comprises reducedexonuclease activity as compared to a wild type polymerase. For example,in certain embodiments, the altered polymerase comprises substitutionmutations at positions functionally equivalent to Asp141 and/or Glu143in the 9° N DNA polymerase amino acid sequence.

In certain embodiments, the altered polymerase further comprisessubstitution mutations at positions functionally equivalent to Ala485 inthe 9° N DNA polymerase amino acid sequence. For example, in someembodiments, the polymerase comprises a substitution mutationfunctionally equivalent to Ala485Leu or Ala485Val in the 9° N polymeraseamino acid sequence.

In certain embodiments, the altered polymerase further comprises asubstitution mutation to a different amino acid at the positionfunctionally equivalent to Cys223 in the 9° N DNA polymerase amino acidsequence. For example, in certain embodiments, the altered polymerasecomprises a substitution mutation functionally equivalent to Cys223Scrin the 9° N polymerase amino acid sequence.

In certain embodiments, the at least one substitution mutation comprisesa mutation to the position equivalent to Thr514, Lys477 and/or Ile521.For example, in certain embodiments, the altered polymerase comprises asubstitution mutation functionally equivalent to Thr514Ala, Thr514Ser,Lys477Met and/or Ile521Leu in the 9° N polymerase amino acid sequence.

In certain embodiments, the altered polymerase can comprise anadditional substitution mutation to remove an internal methionine. Forexample, in some embodiments, the altered, polymerase comprises asubstitution mutation to a different amino acid at the positionfunctionally equivalent of Met 129 in the 9° N DNA polymerase amino acidsequence. In certain embodiments, the altered polymerase comprises asubstitution mutation functionally equivalent to Metl29Ala in the 9° Npolymerase amino acid sequence.

Also presented herein is an altered polymerase comprising a substitutionmutation to the semi-conserved domain comprising the amino acid sequenceof SEQ ID NO: 1 wherein the substitution mutation comprises a mutationselected from a substitution at position 5 to any residue other than Thror Val. In some embodiments, the mutation comprises a substitution atposition 5 to Ala, Gly or Leu.

Also presented herein Ls an altered polymerase comprising a substitutionmutation to the semi-conserved domain comprising the amino acid sequenceof SEQ ID NO: 2 wherein the substitution mutation comprises a mutationselected from a substitution at position 7 to any residue other thanGly, Ala or Lys. In some embodiments, the mutation comprises asubstitution at position 7 to Asp.

Also presented herein is an altered polymerase comprising a substitutionmutation to the semi-conserved domain comprising the amino acid sequenceof any of SEQ ID NOs: 3-6 wherein the substitution mutation comprises amutation selected from a substitution at position 2 to any residue otherthan Lys, Arg, Tyr or Glu. In some embodiments, the mutation comprises asubstitution at position 2 to Trp.

Also presented herein is an altered polymerase comprising a substitutionmutation to the semi-conserved domain comprising the amino acid sequenceof any of SEQ ID NOs: 3-6 wherein the substitution mutation comprises amutation selected from a substitution at position 4 to any residue otherthan Leu, Ile or Ala. In some embodiments, the mutation comprises asubstitution at position 4 to Ser, Arg or Thr.

Also presented herein is an altered polymerase comprising a substitutionmutation to the semi-conserved domain comprising the amino acid sequenceof SEQ ID NO: 7 wherein the substitution mutation comprises a mutationselected from a substitution at position 6 to any residue other thanThr. In some embodiments, the mutation comprises a substitution atposition 6 to Ile or Gly.

Also presented herein is an altered polymerase comprising a substitutionmutation to the semi-conserved domain comprising the amino acid sequenceof SEQ ID NO: 8 wherein the substitution mutation comprises a mutationselected from a substitution at position 6 to any residue other thanAla. In some embodiments, the mutation comprises a substitution atposition 6 to Val or Phe.

Also presented herein is an altered polymerase comprising a substitutionmutation to the semi-conserved domain comprising the amino acid sequenceof SEQ ID NO: 9 wherein the substitution mutation comprises a mutationselected from a substitution at position 7 to any residue other than Aspor Glu. In some embodiments, the mutation comprises a substitution atposition 7 to Asn.

In some embodiments, in addition to the above mutations, the alteredpolymerase can further comprise substitution mutations at positionsfunctionally equivalent to Leu408 and/or Tyr409 and/or Pro410 in the 9°N DNA polymerase amino acid sequence. For example, the substitutionmutations can comprise substitution mutations homologous to Leu408Alaand/or Tyr409Ala and/or Pro410Ile in the 9° N DNA polymerase amino acidsequence.

In some embodiments, the altered polymerase comprises reducedexonuclease activity as compared to a wild type polymerase. For example,in certain embodiments, the altered polymerase comprises substitutionmutations at positions functionally equivalent to Asp 141 and/or GIu 143in the 9° N DNA polymerase amino acid sequence. In certain embodiments,the altered polymerase further comprises substitution mutations atpositions functionally equivalent to Ala485 in the 9° N DNA polymeraseamino acid sequence. For example, in some embodiments, the polymerasecomprises a substitution mutation functionally equivalent to Ala485Leuor Ala485Vaf in the 9° N polymerase amino acid sequence.

In certain embodiments, the altered polymerase further comprises asubstitution mutation to a different amino acid at the positionfunctionally equivalent to Cys223 in the 9° N DNA polymerase amino acidsequence. For example, in certain embodiments, the altered polymerasecomprises a substitution mutation functionally equivalent to Cys223Serin the 9° N polymerase amino acid sequence.

In certain embodiments, the at least one substitution mutation comprisesa mutation to the position equivalent to Thr514, Lys477 and/or Ile521.For example, in certain embodiments, the altered polymerase comprises asubstitution mutation functionally equivalent to Thr514Ala, Thr514Ser,Lys477Met and/or Ile521Leu in the 9° N polymerase amino acid sequence.

In certain embodiments, the altered polymerase can comprise anadditional substitution mutation to remove an internal methionine. Forexample, in some embodiments, the altered polymerase comprises asubstitution mutation to a different amino acid at the positionfunctionally equivalent to Met129 in the 9° N DNA polymerase amino acidsequence. In certain embodiments, the altered polymerase comprises asubstitution mutation functionally equivalent to Met129Ala in the 9° Npolymerase amino acid sequence.

Also presented herein is an altered polymerase comprising the amino acidsequence of any one of SEQ ID NOs: 11-12, 14-15, 17, 19-20, 22-23,25-26, 28,30 and 32-40.

Also presented herein is a nucleic acid molecule encoding an alteredpolymerase as defined in any the above embodiments. Also presentedherein is an expression vector comprising the nucleic acid moleculedescribed above. Also presented herein is a host cell comprising thevector described above.

Also presented herein is a method for incorporating modified nucleotidesinto DNA comprising allowing the following components to interact: (i)an altered polymerase according to any of the above embodiments, (ii) aDNA template; and (iii) a nucleotide solution. In certain embodiments,the DNA template comprises a clustered array.

Also provided herein is a kit for performing a nucleotide incorporationreaction comprising: a polymerase as defined in any of the aboveembodiments and a nucleotide solution. In certain embodiments, thenucleotide solution comprises labelled nucleotides. In certainembodiments, the nucleotides comprise synthetic nucleotides. In certainembodiments, the nucleotides comprise modified nucleotides. In certainembodiments, the modified nucleotides have been modified at the 3′ sugarhydroxyl such that the substituent is larger in size than the naturallyoccurring 3′ hydroxyl group. In certain embodiments, the modifiednucleotides comprise a modified nucleotide or nucleoside moleculecomprising a purine or pyrimidine base and a ribose or deoxyribose sugarmoiety having a removable 3′-OH blocking group covalently attachedthereto, such that the 3′ carbon atom has attached a group of thestructure

—O—Z

wherein Z is any of —C(R′)₂—O—R″, —C(R′)₂—N(R″)₂, —C(R′)₂—N(H)R″,—C(R′)₂—S—R″ and —C(R′)₂—F,

wherein each R″ is or is part of a removable protecting group;

each R′ is independently a hydrogen atom, an alkyl, substituted alkyl,arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclic, acyl,cyano, alkoxy, aryloxy, heteroaryloxy or amido group, or a detectablelabel attached through a linking group; or (R′)₂ represents analkylidene group of formula ═C(R′″)₂ wherein each R″ may be the same ordifferent and is selected from the group comprising hydrogen and halogenatoms and alkyl groups; and

wherein the molecule may be reacted to yield an intermediate in whicheach R″ is exchanged for H or, where Z is —C(R′)₂—F, the F is exchangedfor OH, SH or NH₂, preferably OH, which intermediate dissociates underaqueous conditions to afford a molecule with a free 3′OH;

with the proviso that where Z is —C(R′)₂—S—R″, both R′ groups are not H.

In certain embodiments, R′ of the modified nucleotide or nucleoside isan alkyl or substituted alkyl. In certain embodiments, —Z of themodified nucleotide or nucleoside is of formula —C(R′)₂—N₃. In certainembodiments, Z is an azidomethyl group.

In certain embodiments, the modified nucleotides are fluorescentlylabelled to allow their detection. In certain embodiments, the modifiednucleotides comprise a nucleotide or nucleoside having a base attachedto a detectable label via a cleavable linker. In certain embodiments,the detectable label comprises a fluorescent label. In certainembodiments, the kit further comprises one or more DNA templatemolecules and/or primers.

The details of one or more embodiments are set forth in the accompanyingdrawings and the description below. Other features, objects, andadvantages will be apparent from the description and drawings, and fromthe claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic showing alignment of polymerase amino acidsequences from Thermococcus sp. 9° N-7 (9° N), 9° N polymeraseT514S/1S21L mutant (Pol957), Thermococcus gorgonarius (TGO),Thermococcus kodakaraerisis (KOD1), Pyrococcus furiosus (Pfu),Methanococcus maripuludis (MMS2) and RB69 phage DNA polymerase. Thenumbering shown represents the numbering of amino acid, residues in 9° Npolymerase.

FIG. 2 is a schematic showing two highlighted portions of the alignmentshown in FIG. 1.

DETAILED DESCRIPTION

Presented herein are polymerase enzymes for improved incorporation ofnucleotide analogues, in particular nucleotides which are modified atthe 3′ sugar hydroxyl such that the substituent is larger in size thanthe naturally occurring 3′ hydroxyl group. The present inventors havesurprisingly identified certain altered polymerases which exhibitimproved incorporation of the desired analogues and have a number ofother associated advantages, including reduced error rate, reducedphasing and/or prephasing, and improved quality metrics in sequencing bysynthesis reactions.

As described in greater detail hereinbelow, the inventors havesurprisingly found that one or more mutations to one or more residues inthe polymerase result in profound increases in turnover rate andreduction in pyrophosphorolysis. These altered polymerases have improvedperformance in DNA sequencing by synthesis (SBS) and result in reducedphasing and/or pre-phasing, and overall improved quality metrics insequencing by synthesis reactions.

Phasing and pre-phasing are terms known to those of skill in the art andre used to describe the loss of synchrony in the readout of the sequencecopies of a cluster. Phasing and pre-phasing cause the extractedintensities for a specific cycle to consist of the signal of the currentcycle as well as noise from the preceding and following cycles. Thus, asused herein, the term “phasing” refers to a phenomenon in SBS that iscaused by incomplete incorporation of a nucleotide in some portion ofDNA strands within clusters by polymerases at a given sequencing cycle,and is thus a measure of the rate at which single molecules within acluster loose sync with, each other. Phasing can be measured duringdetection of cluster signal at each cycle, and can be reported as apercentage of detectable signal from a cluster that is out of synchronywith the signal in the cluster. As an example, a cluster is detected bya “green” fluorophore signal during cycle N. In the subsequent cycle(cycle N+1), 99.9% of the cluster signal is detected in the “red”channel and 0.1% of the signal remains from the previous cycle and isdetected in the “green” channel. This result would indicate that phasingis occurring, and can be reported as a numerical value, such as aphasing value of 0.1, indicating that 0.1% of the molecules in thecluster are failing behind at each cycle.

The term “pre-phasing” as used herein refers to a phenomenon in SBS thatis caused by the incorporation of nucleotides without effective 3′terminators, causing the incorporation event to go 1 cycle ahead. As thenumber of cycles increases, the fraction of sequences per clusteraffected by phasing increases, hampering the identification of thecorrect base. Pre-phasing can be detected by a sequencing instrument andreported as a numerical value, such as a pre-phasing value of 0.1,indicating that 0.1% of the molecules in the cluster are running aheadat each cycle.

Detection of phasing and pre-phasing can be performed and reportedaccording to any suitable methodology as is known in the art, torexample, as described in U.S. 2012-0020537, which is incorporated byreference in its entirety. For example, as described in the Examplesbelow, phasing is detected and reported routinely during SBS sequencingruns on sequencing instrument such as HiSeq. Genome Analyzer, NextSeq orMiSeq sequencing platforms from Illumina, Inc. (San Diego, Calif.) orany other suitable instrument known in the art.

Phasing can be caused, for example, by a polymerase which performs thereverse reaction of nucleotide incorporation, as is known to happenunder conditions conducive to pyrophosphorolysis. Accordingly, thediscovery of altered polymerases which decrease the incidence of phasingand/or pre-phasing is surprising and provides a great advantage in SBSapplications. For example, the altered polymerases provide faster SBScycle time, lower phasing and pre-phasing values, and longer sequencingread length. The characterization of phasing and pre-phasing for alteredpolymerases as provided herein is set forth in the Example sectionbelow.

The fidelity with which a sequenced library matches the original genomesequence can vary depending on the frequency of base mutation occurringat any stage from the extraction of the nucleic acid to its sequencingon a sequencing platform. This frequency places an upper limit on theprobability of a sequenced base being correct. In some embodiments, thequality score is presented as a numerical value. For example, thequality score can be quoted as QXX where the XX is the score and itmeans that that particular call has a probability of error of10^(−XX/10). Thus, as an example, Q30 equates to an error rate of 1 in1000, or 0.1% and Q40 equates to an error rate of 1 in 10,000 or 0.01%.Put another way, if a mutation occurs one in a thousand times, then themaximum confidence (probability) that any base is correct is one in a10³, i.e., a max of Q30.

In certain, embodiments, the substitution mutation comprises a mutationto a residue having a non-polar side chain. Amino acids having non-polarside chains are well-known in the art and include, for example; alanine,cysteine, glycine, isoleucine, leucine, methionine, phenylalanine,prolific, tryptophan, tyrosine and valine.

In certain embodiments, the substitution mutation comprises a mutationto a residue having a polar side chain. Amino acids having polar sidechains are well-known in the art and include, for example: arginine,asparagine, aspartic acid, glutamine, glutamic acid, histidine, lysine,serine and threonine.

In certain embodiments, the substitution mutation comprises a mutationto a residue having a hydrophobic side chain. Amino acids havinghydrophobic side chains are well-known in the art and include, forexample: glycine, alanine, valine, leucine, isoleucine, proline,phenylalanine, methionine, and tryptophan.

In certain embodiments, the substitution mutation comprises a mutationto a residue having an uncharged side chain. Amino acids havinguncharged side chains are well-known in the art and include, forexample: glycine, serine, cysteine, asparagine, glutamine, tyrosine, andthreonine.

Also presented herein is an altered polymerase comprising a substitutionmutation to a semi-conserved domain of the polymerase. As used herein,the term “semi-conserved domain” refers to a portion of polymerase thatis fully conserved, or at least partially conserved among variousspecies. It has been surprisingly discovered that mutation of one ormore residues in a semi-conserved domain affects the polymerase activityin the presence of 3′ blocked nucleotides, resulting in profoundlyimproved performance in DNA sequencing by synthesis and result inreduced phasing errors, as described in the Example section below.

An alignment, showing the conservation among various polymerases in thesemi-conserved domains is set forth in FIGS. 1 and 2. The polymerasesequences shown in FIGS. 1 and 2 were obtained from Genbank databaseaccession numbers Q56366 (9° N DNA polymerase), NP_577941 (Pfu),YP_182414 (KOD1), NP_987500 (MMS2), AAP75958 (RB69), P56689 (TGo).

In some embodiments, the semi-conserved domain comprises amino acidshaving the sequence set forth in SEQ ID NO: 1. SEQ ID NO: 1 sets forthresidues in the semi-conserved domain that are conserved among variouspolymerases, and corresponds to residues 140-149 of the 9° N DNApolymerase amino acid sequence, which is set forth herein as SEQ ID NO:10. Accordingly, in some embodiments of the altered polymerasespresented herein comprising a substitution mutation to a semi-conserveddomain of the polymerase, the substitution mutation comprises a mutationat position 5 of SEQ ID NO: 1 to any residue other than other than Thror Val. In certain embodiments, the altered polymerase comprises amutation to a non-polar residue at position 5 of SEQ ID NO: 1 In certainembodiments, the altered polymerase comprises a mutation to Ala, Gly orLeu at position 5 of SEQ ID NO: 1.

In some embodiments, the semi-conserved domain comprises amino acidshaving the sequence set forth in SEQ ID NO: 2. SEQ ID NO: 2 sets forthresidues in the semi-conserved domain that are conserved among variouspolymerases, and corresponds to residues 147-157 of the 9° N DNApolymerase amino acid sequence, which is set forth herein as SEQ ID NO:10. Accordingly, in some embodiments of the altered polymerasespresented herein comprising a substitution mutation to a semi-conserveddomain of the polymerase, the substitution mutation comprises a mutationat position 7 of SEQ ID NO: 2 to any residue other than other than Gly,Ala or Lys. In certain embodiments, the altered polymerase comprises amutation to a polar residue at position 7 of SEQ ID NO: 2. In certainembodiments, the altered polymerase comprises a mutation to Asp atposition 7 of SEQ ID NO: 2.

In some embodiments, the semi-conserved domain comprises amino acidshaving the sequence set forth in any of SEQ ID NOs: 3-6. SEQ ID NOs: 3-6set forth residues in the semi-conserved domain that are conserved amongvarious polymerases, and corresponds to residues 475-492 of the 9° N DNApolymerase amino acid sequence, which is set forth herein as SEQ ID NO:10. Accordingly, in some embodiments of the altered polymerasespresented herein comprising a substitution mutation to a semi-conserveddomain of the polymerase, the substitution mutation comprises a mutationat position 2 of any of SEQ ID NOs: 3-6 to any residue other than otherthan Lys, Arg, Tyr or Glu. In certain embodiments, the alteredpolymerase comprises a mutation to a hydrophobic residue at position 2of any of SEQ ID NOs: 3-6, In certain embodiments, the alteredpolymerase comprises a mutation to Trp at position 2 of any of SEQ. IDNOS: 3-6.

In some embodiments of the altered polymerases presented hereincomprising a substitution mutation to a semi-conserved domain of thepolymerase, the substitution mutation comprises a mutation at position 4of any of SEQ ID NOs: 3-6 to any residue other than other than Leu, Ileor Ala. In certain embodiments, the altered polymerase comprises amutation to a polar residue at position 4 of any of SEQ ID NOs: 3-6. Incertain embodiments, the altered polymerase comprises a mutation to Ser,Arg or Thr at position 4 of any of SEQ ID NOs: 3-6.

In some embodiments, the semi-conserved domain comprises amino acidshaving the sequence set forth in SEQ ID NO: 7. SEQ ID NO: 7 sets forthresidues in the semi-conserved domain that are conserved among variouspolymerases, and corresponds to residues 585-598 of the 9° N DNApolymerase amino acid sequence, which is set forth herein as SEQ ID NO:10. Accordingly, in some embodiments of the altered polymerasespresented herein comprising a substitution mutation to a semi-conserveddomain of the polymerase, the substitution mutation comprises a mutationat position 6 of SEQ ID NO: 7 to any residue other than other than Thr.In certain embodiments, the altered polymerase comprises a mutation to anon-polar residue at position 6 of SEQ ID NO: 7. In certain embodiments,the altered polymerase comprises a mutation to Ile or Gly at position 6of SEQ ID NO: 7.

In some embodiments, the semi-conserved domain comprises amino acidshaving the sequence set forth in SEQ ID NO: 8. SEQ ID NO: 8 sets forthresidues in the semi-conserved domain that are conserved among variouspolymerases, and corresponds to residues 634-646 of the 9° N DNApolymerase amino acid sequence, which is set forth herein as SEQ ID NO:10. Accordingly, in some embodiments of the altered polymerasespresented herein comprising a substitution mutation to a semi-conserveddomain of the polymerase, the substitution mutation comprises a mutationat position 6 of SEQ ID NO: 8 to any residue other than other than Alaor Gln. In certain embodiments, the altered polymerase comprises amutation to Val or Phe at position 6 of SEQ ID NO: 8.

In some embodiments, the semi-conserved domain comprises amino acidshaving the sequence set forth in SEQ ID NO: 9. SEQ ID NO: 9 sets forthresidues in the semi-conserved domain that are conserved among variouspolymerases, and corresponds to residues 712-722 of the 9° N DNApolymerase amino acid sequence, which is set forth herein as SEQ ID NO:10. Accordingly, in some embodiments of the altered polymerasespresented herein comprising a substitution mutation to a semi-conserveddomain of the polymerase, the substitution mutation comprises a mutationat position 7 of SEQ ID NO: 9 to any residue other than other than Asp,Glu or Gly. In certain embodiments, the altered polymerase comprises amutation to an uncharged residue at position 7 of SEQ ID NO: 9. Incertain embodiments, the altered polymerase comprises a mutation to Asnat position 7 of SEQ ID NO: 9.

In some embodiments, the polymerase is a DNA polymerase. In certainembodiments, the DNA polymerase is a family B type DNA polymerase. Thepolymerase can be, for example, a family B archael DNA polymerase, humanDNA polymerase-α, and phage polymerases. Any phage polymerase can beused in the embodiments presented herein, including, for example phagepolymerases such as T4, RB69, and phi29 phage DNA polymerases.

Family B archael DNA polymerases are well known in the art asexemplified by the disclosure of U.S. Pat. No. 8,283,149, which isincorporated by reference in its entirety. In certain embodiments thearchael DNA polymerase is from hyperthermophilic archea, which meansthat the polymerases are often thermostable. Accordingly, in a furtherpreferred embodiment the polymerase is selected from Vent, Deep Vent, 9°N and Pfu polymerase. Vent and Deep Vent are commercial names used forfamily B DNA polymerases isolated from the hyperthermophilic archaeonThermococcus litoralis. 9° N polymerase was also identified fromThermococcus sp. Pfu polymerase was isolated from Pyrococcus furiosus.

In certain embodiments, the family B archael DNA polymerase is from agenus such as, tor example those of the genus Thermococcus, Pyrococcusand Methanococcus. Members of the genus Thermococcus are well known inthe art and include, but are not limited to Thermococcus 4557,Thermococcus barophilus, Thermococcus gammatolerans, Thermococcusonnurineus, Thermococcus sibiricus, Thermococcus kodakarensis,Thermococcus gorgonarius. Members of the genus Pyrococcus are well knownin the art and include, but are not limited to Pyrococcus NA2,Pyrococcus abyssi, Pyrococcus furiosus, Pyrococcus horikoshii,Pyrococcus yayanosii, Pyrococcus endeavori, Pyrococcus glycovorans,Pyrococcus woesei. Members of the genus Methanococcus are well known inthe art and include, but are not limited to M. aeolicus, M. maripaludis,M. vannielii, M. voltae, “M. thermolithotrophicus” and “M. jannaschii”.

For example, the polymerase can be selected from the group consisting ofVent, Deep Vent, 9° N, and Pfu polymerase. In certain embodiments, thefamily B archael DNA polymerase is 9° N polymerase.

By “functionally equivalent” it is meant that, the control polymerase,in the case of studies using a different polymerase entirely, willcontain the amino acid substitution that is considered to occur at theamino acid position in the other polymerase that has the same functionalrole in the enzyme. As an example, the mutation at position 412 fromTyrosine to Valine (Y412V) in the Vent DNA polymerase would befunctionally equivalent to a substitution at position 409 from Tyrosineto Valine (Y409V) in the 9° N polymerase.

Generally functionally equivalent substitution mutations in two or moredifferent polymerases occur at homologous amino acid positions in theamino acid sequences of the polymerases. Hence, use herein of the term“functionally equivalent” also encompasses mutations that are“positionally equivalent” or “homologous” to a given mutation,regardless of whether or not the particular function of the mutatedamino acid is known. It is possible to identify positionally equivalentor homologous amino acid residues in the amino acid sequences of two ormore different polymerases on the basis of sequence alignment and/ormolecular modelling. An example of sequence alignment to identifypositionally equivalent and/or functionally equivalent residues is setforth in FIGS. 1 and 2. Thus, for example, as shown in FIG. 2, theresidues in the semi-conserved domain identified as positions 475-492 ofthe 9° N DNA polymerase amino acid sequence. The corresponding residuesin TGO, KOD1, Pfu, MmS2 and RB69 polymerases are identified in theFigure as vertically aligned and are considered positionally equivalentas well as functionally equivalent to the corresponding residue in the9° N DNA polymerase amino acid sequence.

The altered polymerases described hereinabove can comprise additionalsubstitution mutations that are known to enhance one or more aspects ofpolymerase activity in the presence of V blocked nucleotides and/or inDNA sequencing applications. For example, in some embodiments, inaddition to any of the above mutations, the altered polymerase canfurther comprise substitution mutations at positions functionallyequivalent to Leu408 and/or Tyr409 and/or Pro410 in the 9° N DNApolymerase amino acid sequence. Any of a variety of substitutionmutations at one or more of positions at positions functionallyequivalent to 408-410 in the 9° N DNA polymerase amino acid sequencewhich results in increased incorporation, of blocked nucleotides can bemade, as is known in the art and exemplified by the disclosure of US2006/0240439 and US 2006/0281109, each of which is incorporated byreference in its entirety. For example, the substitution mutations cancomprise substitution mutations homologous to Leu408Ala and/or Tyr409Alaand/or Pro410Ile in the 9° N DNA polymerase amino acid sequence. Incertain embodiments, in addition to any of the above mutations, thealtered polymerase further comprises substitution mutations at positionsfunctionally equivalent to Ala485 in the 9° N DNA polymerase amino acidsequence. For example, in some embodiments, the polymerase comprises asubstitution mutation functionally equivalent to Ala485Leu or Ala485Valin the 9° N polymerase amino acid sequence.

In some embodiments, in addition to any of the above mutations, thealtered polymerase can comprise reduced exonuclease activity as comparedto a wild type polymerase. Any of a variety of substitution mutations atone or more of positions known to result in reduced exonuclease activitycan be made, as is known in the art and exemplified by the incorporatedmaterials of US 2006/0240439 and US 2006/0281109. For example, in someembodiments, in addition to the above mutations, the altered polymerasecan further comprise substitution mutations at positions functionallyequivalent to Asp141 and/or Glu 143 in the 9° DNA polymerase amino acidsequence.

In certain embodiments, in addition to any of the above mutations, thealtered polymerase further comprises a substitution mutation to adifferent amino acid at the position functionally equivalent, to Cys223in the 9° N DNA polymerase amino acid sequence as is known in the artand exemplified by the incorporated materials of US 2006/0281109, Forexample, in certain embodiments, the altered polymerase comprises asubstitution mutation functionally equivalent to Oys223Ser in the 9° Npolymerase amino acid sequence.

In certain embodiments, in addition to any of the above mutations, thealtered polymerase can comprise one or more mutation to the positionsequivalent to Tbr514 and/or Ile52l in the 9° N DNA polymerase amino acidsequence as is known in the art and exemplified by the disclosure ofPCT/US2013/031694, which is incorporated by reference in its entirety.For example, in certain embodiments, the altered polymerase comprises asubstitution mutation functionally equivalent to Thr514Ala, Thr514Serand/or Ile521Leu in the 9° N polymerase amino acid sequence.

In certain embodiments, in addition to any of the above mutations, thealtered polymerase can comprise one or more mutation to the positionsequivalent to Arg 13 in the 9° N DNA polymerase amino acid sequence asis known in the art and exemplified by the disclosure of U.S. Pat. No.8,623,628, which is incorporated by reference in its entirety, forexample, in certain embodiments, the altered polymerase comprises asubstitution mutation functionally equivalent to Arg713Gly, Arg713Met orArg7l3Ala in the 9° N polymerase amino acid sequence.

In certain embodiments, in addition to any of the above mutations, thealtered polymerase can comprise one or more mutation to the positionsequivalent to Arg43 and/or Lys70S in the 9° N DNA polymerase amino acidsequence, as is known in the art and exemplified by the disclosure ofU.S. Pat. No. 8,623,628, which is incorporated by reference in itsentirety. For example, in certain embodiments, the altered polymerasecomprises a substitution mutation functionally equivalent to Arg743Alaand/or Lys705Ala in the 9° N polymerase amino acid sequence.

In certain embodiments, in addition to any of the above mutations, thealtered polymerase can comprise one or more mutation to the positionsequivalent to Lys477 in the 9° N DNA polymerase amino acid sequence asis known in the art and exemplified by the disclosure of U.S.Application 62/018,470, filed on Jun. 27, 2014 and entitled “MODIFIEDPOLYMERASES FOR IMPROVED INCORPORATION OF NUCLEOTIDE ANALOGUES”, whichis incorporated by reference in its entirety. For example, in certainembodiments, the altered polymerase comprises a substitution mutationfunctionally equivalent to Lys477Met in the 9° N polymerase amino acidsequence.

In certain embodiments, in addition to any of the above mutations, thealtered polymerase can comprise one or more additional substitutionmutation to remove an internal methionine. For example, in someembodiments, the altered polymerase comprises a substitution mutation toa different amino acid at the position functionally equivalent to Met129in the 9° N DNA polymerase amino acid sequence. In certain embodiments,the altered polymerase comprises a substitution mutation functionallyequivalent to Met129Ala in the 9° N polymerase amino acid sequence.

Mutating Polymerases

Various types of mutagenesis are optionally used in the presentdisclosure, e.g., to modify polymerases to produce variants, e.g., inaccordance with polymerase models and model predictions as discussedabove, or using random or semi-random mutational approaches. In general,any available mutagenesis procedure can be used for making polymerasemutants. Such mutagenesis procedures optionally include selection ofmutant nucleic acids and polypeptides for one or more activity ofinterest (e.g., reduced pyrophosphonolysis, increased turnover e.g., fora given nucleotide analog). Procedures that can be used include, but arenot limited to: site-directed point mutagenesis, random pointmutagenesis, in vitro or in vivo homologous recombination (DNA shufflingand combinatorial overlap PCR), mutagenesis using uracil containingtemplates, oligonucleotide-directed mutagenesis,phosphorothioate-modificd DNA mutagenesis, mutagenesis using gappedduplex DNA, point mismatch repair, mutagenesis using repair-deficienthost strains, restriction-selection and restriction-purification,deletion mutagenesis, mutagenesis by total gene synthesis, degeneratePCR, double-strand break repair, and many others known to persons ofskill. The starting polymerase for mutation can be any of those notedherein, including available polymerase mutants such as those identifiede.g., in US 2006/0240439 and US 2006/0281109. each of which isincorporated by reference in its entirety.

Optionally, mutagenesis can be guided by known information from anaturally occurring polymerase molecule, or of a known altered ormutated polymerase (e.g., using an existing mutant polymerase as notedin the preceding references), e.g., sequence, sequence comparisons,physical properties, crystal structure and/or the like as discussedabove. However, in another class of embodiments, modification can beessentially random (e.g., as in classical or “family” DNA shuffling,see, e.g., Crameri et al. (1998) “DNA shuffling of a family of genesfrom diverse species accelerates directed evolution” Nature391.288-291).

Additional information on mutation formats is found in: Sambrook et al.,Molecular Cloning—A Laboratory Manual (3rd Ed.), Vol. 1-3, Cold SpringHarbor Laboratory, Cold Spring Harbor, N.Y., 2000 (“Sambrook”); CurrentProtocols in Molecular Biology, F. M. Ausubel et at, eds., CurrentProtocols, a joint venture between Greene Publishing Associates, Inc.and John Wiley & Sons, Inc., (supplemented through 2011) (“Ausubel”))and PCR Protocols A Guide to Methods and Applications (Innis et al. eds)Academic Press Inc. San Diego, Calif (1990) (“Innis”). The followingpublications and references cited within provide additional detail onmutation formats: Arnold, Protein engineering for unusual environments,Current Opinion in Biotechnology 4:450-455 (1993); Bass et al. MutantTrp repressors with new DNA-binding specificities, Science 242:240-245(1988): Bordo and Argos (1991) Suggestions for “Safe” ResidueSubstitutions in Site-directed Mutagenesis 217:721-729; Botstein &Shortle, Strategies and applications of in vitro mutagenesis, Science229:1193-1201 (1985); Carter et al., Improved oligonucleotidesite-directed mutagenesis using M13 vectors, NucL Acids Res. 13:4431-1443 (1985); Carter, Site-directed mutagenesis, Biochem.. .1.237:1-7 (1986); Carter, Improved oligonucleotide-directed mutagenesisusing M13 vectors, Methods in Enzymol. 154: 382-403 (1987); Dale et al,Oligonucleotide-directed random mutagenesis using the phosphorothioatemethod, Methods Mol. Biol 57:369-374 (1996); Eghtedarzadeh & Henikoff,Use of oligonucleotides to generate large deletions, Nucl. Acids Res.14: 5115 (1986); Fritz et al., Oligonucleotide-directed construction ofmutations: a gapped duplex DNA procedure without enzymatic reactions invitro. Nucl. Acids Res. 16; 6987-6999 (1988); Grundstrom et al.,Oligonucleotide-directed mutagenesis by microscale ‘shot-gun’ genesynthesis, Nucl Acids Res. 13: 3305-3316 (1985); Hayes (2002) CombiningComputational and Experimental Screening for rapid Optimization ofProtein Properties PNAS 99(25) 15926-15931: Kunkel, The efficiency ofoligonucleotide directed mutagenesis, in Nucleic Acids & MolecularBiology (Eckstein, F. and Lilley, D. M. J. eds., Springer Verlag,Berlin)) (1987); Kunkel, Rapid and efficient site-specific mutagenesiswithout phenotypic selection, Proc. Natl Acad. Sci. USA 82:488-492(1985); Kunkel et al, Rapid and efficient site-specific mutagenesiswithout phenotypic selection, Methods in Enzymol. 154, 367-382 (1987);Kramer et al., The gapped duplex DNA approach tooligonucleotide-directed mutation construction, Nucl. Acids Res. 12:9441-9456 (1984); Kramer & Fritz Oligonucleotide-directed constructionof mutations via gapped duplex DNA, Methods in Enzymol. 154:350-367(1987); Kramer et al., Point Mismatch Repair, Cell 38:879-887 (1984);Kramer et al. Improved enzymatic in vitro reactions in the gapped duplexDNA approach to oligonucleotide-directed construction of mutations,Nucl. Acids Res. 16: 7207 (1988); Ling et at. Approaches to DNAmutagenesis: an overview, Anal Biochem. 254(2): 157-178 (1997); Lorimerand Pastan Nucleic Acids Res. 23, 3067-8 (1995); Mandecki,Oligonucleotide-directed double-strand break repair in plasmids ofEscherichia coli: a method for site-specific mutagenesis, Proc. Natl.Acad. Set USA, 83:7177-7181(1986); Nakamaye & Eckstein, Inhibition ofrestriction endonuclease Nci I cleavage by phosphorothioate groups andits application to oligonucleotide-directed mutagenesis, Nucl. AcidsRes. 14: 9679-9698 (1986); Nambiar et al., Total synthesis and cloningof a gene coding for the ribonuclease S protein, Science 223:1299-13010984); Sakamar and Khorana, Total synthesis and expression of agene for the a-subunit of bovine rod outer segment guaninenucleotide-binding protein (transducin), Nucl. Acids Res. 14: 6361-6372(1988); Sayers et at, Y-T Exonucleases in phosphorothioate-basedoligonucleotide-directed mutagenesis, Nucl. Acids Res. 16:791-802(1988); Sayers et al., Strand specific cleavage ofphosphorothioate-containing DNA by reaction with restrictionendonucleases in the presence of ethidium bromide, (1988) Nucl. AcidsRes. 16: 803-814; Sieber, et al., Nature Biotechnology, 19:456-460(2001); Smith, In vitro mutagenesis, Ann. Rev. Genet. 19:423-462 (1985);Methods in Enzymol. 100: 468-500 (1983); Methods in Enzymol. 154:329-350 (1987); Stemmer. Nature 370, 389-91(1994); Taylor et al., Theuse of phosphorothioate-modified DNA in restriction enzyme reactions toprepare nicked DNA, Nucl. Acids Res. 13: 8749-8764 (1985); Taylor etal., The rapid generation of oligonucleotide-directed mutations at highfrequency using phosphorothioate-modified DNA, Nucl. Acids Res. 13:8765-8787 (1985): Wells et al., Importance of hydrogen-bond formation instabilizing the transition state of subtilisin, Phil. Trans. R. Soc.Lorid. A 317: 415-423 (1986); Wells et al., Cassette mutagenesis: anefficient method for generation of multiple mutations at defined sites,Gene 34:315-323 (1985); Zoller & Smith, Oligonucleotide-directedmutagenesis using M 13-derived vectors: an efficient and generalprocedure for the production of point mutations in any DNA fragment,Nucleic Acids Res. 10:6487-6500 (1982); Zoller & Smith,Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13vectors. Methods in Enzymol. 100:468-500 (1983); Zolier & Smith,OUgonucleotide-directed mutagenesis: a simple method using twooligonucleotide primers and a single-stranded DNA template, Methods inEnzymol, 154:329-350 (1987); Ciackson et al. (1991) “Making antibodyfragments using phage display libraries” Nature 352:624-628; Gibbs etal. (2001) “Degenerate oligonucleotide gene shuffling (DOGS): a methodfor enhancing the frequency of recombination with family shuffling” Gene271; 13-20; and Hiraga and Arnold (2003) “General method forsequence-independent site-directed chimeragenesis: J. Mol. Biol.330:287-296. Additional details on many of the above methods can befound in Methods in Enzymology Volume 154, which also describes usefulcontrols for trouble-shooting problems with various mutagenesis methods.

Making and Isolating Recombinant Polymerases

Generally, nucleic acids encoding a polymerase as presented herein canbe made by cloning, recombination, in vitro synthesis, in vitroamplification and/or other available methods. A variety of recombinantmethods can be used for expressing an expression vector that encodes apolymerase as presented herein. Methods for making recombinant nucleicacids, expression and isolation of expressed products are well known anddescribed in the art. A number of exemplary mutations and combinationsof mutations, as well as strategies for design of desirable mutations,are described herein. Methods for making and selecting mutations in theactive site of polymerases, including for modifying steric features inor near the active site to permit improved access by nucleotide analogsare found hereinabove and, e.g., in WO 2007/076057 andPCT/US2007/022459, which are incorporated by reference in theirentireties.

Additional useful references for mutation, recombinant and in vitronucleic acid manipulation methods (including cloning, expression, PCR,and the like) include Berger and Kimmel Guide to Molecular (ToningTechniques, Methods in Enzymology volume 152 Academic Press, Inc., SanDiego, Calif. (Berger); Kaufman et al. (2003) Handbook of Molecular andCellular Methods in Biology and. Medicine Second Edition Ceske (ed) CIRCPress (Kaufman); and The Nucleic Acid Protocols Handbook Ralph Rapley(ed) (2000) Cold Spring Harbor, Humana Press Inc (Rapley); Chen et al.(ed) PCR Cloning Protocols, Second Edition (Methods in MolecularBiology, volume 192) Humana Press; and in Viljoen et al, (2005)MolecularDiagnostic PCR Handbook Springer, ISBN 1402034032.

In addition, a plethora of kits are commercially available for thepurification of plasmids or other relevant nucleic acids from cells,(see, e.g., EasyPrep.™., FlexiPrep.™. both from Pharmacia Biotech;StrataClean.™., from Stratagene; and, QIAprep.™, from Qiagen). Anyisolated and/or purified nucleic acid can be further manipulated toproduce other nucleic acids, used to transfect cells, incorporated intorelated vectors to infect organisms for expression, and/or the like.Typical cloning vectors contain transcription and translationterminators, transcription and translation initiation sequences, andpromoters useful for regulation of the expression of the particulartarget nucleic acid. The vectors optionally comprise generic expressioncassettes containing at least one independent terminator sequence,sequences permitting replication of the cassette in eukaryotes, orprokaryotes, or both, (e.g., shuttle vectors) and selection markers forboth prokaryotic and eukaryotic systems. Vectors are suitable forreplication and integration in prokaryotes, eukaryotes, or both.

Other useful references, e.g. for cell isolation and culture (e.g., forsubsequent nucleic acid isolation) include Freshney (1994) Culture ofAnimal Cells, a Manual of Basic Technique, third edition, Wiley-Liss,New York and the references cited therein; Payne et al. (1992) PlantCell and Tissue Culture in Liquid Systems John Wiley Sc Sons, Inc. NewYork, N.Y.; Gamborg and Phillips (eds) (1995) Plant Cell, Tissue andOrgan Culture; Fundamental Methods Springer Lab Manual. Springer-Vcrlag(Berlin Heidelberg New York) and Atlas and Parks (eds) The Handbook ofMicrobiological Media (1993) CRC Press, Boca Raton, Fla.

Nucleic acids encoding the recombinant polymerases of disclosed hereinare also a feature of embodiments presented herein. A particular aminoacid can be encoded by multiple codons, and certain translation systems(e.g., prokaryotic or eukaryotic cells) often exhibit codon bias, e.g.,different organisms often prefer one of the several synonymous codonsthat encode the same amino acid. As such, nucleic acids presented hereinare optionally “codon optimized,” meaning that the nucleic acids aresynthesized to include codons that are preferred by the particulartranslation system being employed to express the polymerase. Forexample, when it is desirable to express the polymerase in a bacterialcell (or even a particular strain of bacteria), the nucleic acid can besynthesized to include codons most frequently found in the genome ofthat bacterial cell, for efficient expression of the polymerase. Asimilar strategy can be employed when it is desirable to express thepolymerase in a eukaryotic cell, e.g., the nucleic acid can includecodons preferred by that eukaryotic cell.

A variety of protein isolation and detection methods are known and canbe used to isolate polymerases, e.g., from recombinant cultures of cellsexpressing the recombinant polymerases presented herein. A variety ofprotein isolation and detection methods are well known in the an,including, e.g., those set forth in R. Scopes. Protein Purification,Springer-Verlag, N.Y. (1982); Deutscher, Methods in Enzymology Vol. 182:Guide to Protein Purification, Academic Press, Inc. N.Y. (1990); Sandana(1997) Bioseparation of Proteins, Academic Press, Inc.; Bollag et al.(1996) Protein Methods, 2.sup.nd Edition Wiley-Liss, NY; Walker (1996)The Protein Protocols Handbook Humana Press, NJ, Harris and Angal (1990)Protein Purification Applications: A Practical Approach IRL Press atOxford, Oxford, England; Harris and Angal Protein Purification Methods:A Practical Approach IRL Press at Oxford, Oxford, England; Scopes (1993)Protein Purification: Principles and Practice 3.sup.rd Edition SpringerVerlag, NY; Janson and Ryden (1998) Protein Purification: Principles,High Resolution Methods and Applications, Second Edition Wiley-VCH. NY;and Walker (1998) Protein Protocols on CD-ROM Humana Press, NJ; and thereferences cited therein. Additional details regarding proteinpurification and detection methods can be found in Satinder Abuja ed.,Handbook of Bioseparations, Academic Press (2000).

Methods of Use

The altered polymerases presented herein can be used in a sequencingprocedure, such as a sequencing-by-synthesis (SBS) technique. Briefly,SBS can be initiated by contacting the target nucleic acids with one ormore labeled nucleotides, DNA polymerase, etc. Those features where aprimer is extended using the target nucleic acid as template willincorporate a labeled nucleotide that can be detected. Optionally, thelabeled nucleotides can further include a reversible terminationproperty that terminates further primer extension once a nucleotide hasbeen added to a primer. For example, a nucleotide analog having areversible terminator moiety can be added to a primer such thatsubsequent extension cannot occur until a deblocking agent is deliveredto remove the moiety. Thus, for embodiments that use reversibletermination, a deblocking reagent can be delivered to the flow cell(before or after detection occurs). Washes can be carried out betweenthe various delivery steps. The cycle can then be repeated n times toextend the primer by n nucleotides, thereby detecting a sequence oflength n. Exemplary SBS procedures, fluidic systems and detectionplatforms that can be readily adapted for use with an array produced bythe methods of the present disclosure are described, for example, inBentley et al., Nature 456:53-59 (2008), WO 04/018497; WO 91/06678; WO07/123744; U.S. Pat. Nos. 7,057,026; 7,329,492; 7,211,414; 7.315,019 or7,405,281, and US Pat. App. Pub. No. 2008/0108082 A1. each of which isincorporated herein by reference.

Other sequencing procedures that use cyclic reactions can be used, suchas pyrosequencing, Pyrosequencing detects the release of inorganicpyrophosphate (PPi) as particular nucleotides are incorporated into anascent nucleic acid strand (Ronaghi, et al., Analytical Biochemistry242(1), 84-9 (1996); Ronaghi, Genome Res. 11(1), 3-11 (2001); Ronaghi etal. Science 281(5375), 363 (1998); U.S. Pat. Nos. 6,210,891; 6,258,568and 6,274,320, each of which is incorporated herein by reference). Inpyrosequencing, released PPi can be detected by being converted toadenosine triphosphate (ATP) by ATP sulfurylase, and the resulting ATPcan be detected via luciferase-produced photons. Thus, the sequencingreaction can be monitored via a luminescence detection system.Excitation radiation sources used for fluorescence based detectionsystems are not necessary for pyrosequencing procedures. Useful fluidicsystems, detectors and procedures that can be used for application ofpyrosequencing to arrays of the present disclosure are described, forexample, in WIPO Pat. App. Ser. No. PCT/US11/57111, US Pat. App. Pub.No. 2005/0191698 A1, U.S. Pat. No. 7,595,883. and U.S. Pat. No.7,244,559, each of which is incorporated herein by reference.

Some embodiments can utilize methods involving the real-time monitoringof DNA polymerase activity. For example, nucleotide incorporations canbe detected through fluorescence resonance energy transfer (FRET)interactions between a fluorophore-bearing polymerase andγ-phosphate-labeled nucleotides, or with zeromode waveguides. Techniquesand reagents for FRET-based sequencing are described, for example, inLevene et al. Science 299, 682-686 (2003); Lundquist et al. Opt. Lett.33, 1026-1028 (2008); Korlach et al. Proc. Natl. Acad. Scl USA 105,1176-1181 (2008), the disclosures of which are incorporated herein byreference.

Some SBS embodiments include detection of a proton released uponincorporation of a nucleotide into an extension product. For example,sequencing based on detection of released protons can use an electricaldetector and associated techniques that are commercially available fromIon Torrent (Guilford, Conn. a Life Technologies subsidiary) orsequencing methods and systems described in US Pat. App. Pub. Nos,2009/0026082 A1; 2009/0127589 A1; 2010/0137143 A1; or 2010/0282617 A1,each of which is incorporated herein by reference.

Accordingly, presented herein are methods for incorporating nucleotideanalogues into DNA comprising allowing the following components tointeract: (i) an altered polymerase according to any of the aboveembodiments, (ii ) a DNA template; and (iii) a nucleotide solution. Incertain embodiments, the DNA template comprises a clustered array. Incertain embodiments, the nucleotides are modified at the 3′ sugarhydroxyl, and include modifications at the 3′ sugar hydroxyl such thatthe substituent is larger in size than the naturally occurring 3′hydroxyl group.

Sequence Comparison, identity, and Homology

The terms “identical” or “percent identity,” in the context of two ormore nucleic acid or polypeptide sequences, refer to two or moresequences or subsequences that are the same or have a specifiedpercentage of amino acid residues or nucleotides that are the same, whencompared and aligned for maximum correspondence, as measured using oneof the sequence comparison algorithms described below (or otheralgorithms available to persons of skill) or by visual inspection.

The phrase “substantially identical,” in the context of two nucleicacids or polypeptides (e.g., DNAs encoding a polymerase, or the aminoacid sequence of a polymerase) refers to two or more sequences orsubsequences that have at least about 60%, about 80%, about 90-95%,about 98%, about 99% or more nucleotide or amino acid residue identity,when compared and aligned tor maximum correspondence, as measured usinga sequence comparison algorithm or by visual inspection. Such“substantially identical” sequences are typically considered to be“homologous,” without reference to actual ancestry. Preferably, the“substantial identity” exists over a region of the sequences that is atleast about 50 residues in length, mote preferably over a region of atleast about 100 residues, and most preferably, the sequences aresubstantially identical over at least about 150 residues, or over thefull length of the two sequences to be compared.

Proteins and/or protein sequences are “homologous” when they arederived, naturally or artificially, from a common ancestral protein orprotein sequence. Similarly, nucleic acids and/or nucleic acid sequencesam homologous when they are derived, naturally or artificially, from acommon ancestral nucleic acid or nucleic acid sequence. Homology isgenerally inferred from sequence similarity between two or more nucleicacids or proteins (or sequences thereof). The precise percentage ofsimilarity between sequences that is useful in establishing homologyvaries with the nucleic acid and protein at issue, but as little as 25%sequence similarity over 50, 100, 150 or more residues is routinely usedto establish homology. Higher levels of sequence similarity, e.g., 30%,40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99% or more, can also be used toestablish homology. Methods for determining sequence similaritypercentages (e.g., BLASTP and BLASTN using default parameters) aredescribed herein and are generally available.

For sequence comparison and homology determination, typically onesequence acts as a reference sequence to which test sequences arecompared. When using a sequence comparison algorithm, test and referencesequences are input into a computer, subsequence coordinates aredesignated, if necessary, and sequence algorithm program parameters aredesignated. The sequence comparison algorithm then calculates thepercent sequence identity for the test sequencers) relative to thereference sequence, based on the designated program parameters.

Optimal alignment of sequences for comparison can be conducted, e.g., bythe local homology algorithm of Smith & Waterman, Adv. Appl Math. 2:482(1981), by the homology alignment algorithm of Needleman & Wunsch, J.Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson& Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerizedimplementations of these algorithms (GAP, BESTFIT, FAST A, and TFASTA inthe Wisconsin Genetics Software Package, Genetics Computer Group, 575Science Dr., Madison, Wis.), or by visual inspection (see generallyCurrent Protocols in Molecular Biology, Ausubcl et al., eds., CurrentProtocols, a joint venture between Greene Publishing Associates, Inc.and John Wiley & Sons, Inc., supplemented through 2004).

One example of an algorithm that is suitable for determining percentsequence identity and sequence similarity is the BL AST algorithm, whichis described in Altschul et al., J. Mol. Biol. 215:403-410 (1990).Software tor performing BLAST analyses is publicly available through theNational Center for Biotechnology Information. This algorithm involvesfirst identifying high scoring sequence pairs (HSPs) by identifyingshort words of length W in the query sequence, which either match orsatisfy some positive-valued threshold score T when aligned with a wordof the same length in a database sequence. T is referred to as theneighborhood word score threshold (Altschul et al., supra). Theseinitial neighborhood word hits act as seeds for initiating searches tofind longer HSPs containing them. The word hits are then extended inboth directions along each sequence for as far as the cumulativealignment score can be increased. Cumulative scores are calculatedusing, for nucleotide sequences, the parameters M (reward score for apair of matching residues; always >0) and N (penalty score formismatching residues; always <0). For amino acid sequences, a scoringmatrix is used to calculate the cumulative score. Extension of the wordhits in each direction are halted when: the cumulative alignment scorefalls off by the quantity X from its maximum achieved value; thecumulative score goes to zero or below, due to the accumulation of oneor more negative-scoring residue alignments; or the end of eithersequence is reached. The BLAST algorithm parameters W, T, and Xdetermine the sensitivity and speed of the alignment. The BLASTN program(for nucleotide sequences) uses as defaults a wordiength (W) of 11, anexpectation (E) of 10, a cutoff of 100, M=5, N=−4, and a comparison ofboth strands. For amino acid sequences, the BLASTP program uses asdefaults a wordiength (W) of 3, an expectation (E) of 10, and theBLOSUM62 scoring matrix (sec Henikoff & HenikofT(1989) Proc. Natl. Acad.Sci. USA 89:10915).

In addition to calculating percent sequence identity, the BLASTalgorithm also performs a statistical analysis of the similarity betweentwo sequences (see, e.g., Karlin & Altschul, Proc. Nat'l. Acad. Sci. USA90:5873-5787 (1993)). One measure of similarity provided by the BLASTalgorithm is the smallest sum probability (P(N)), which provides anindication of the probability by which a match between two nucleotide oramino acid sequences would occur by chance. For example, a nucleic acidis considered similar to a reference sequence if the smallest sumprobability in a comparison of the test nucleic acid to the referencenucleic acid is less than about 0.1, more preferably less than about0.01, and most preferably less than about 0.001.

Nucleic Acids Encoding Altered Polymerases

Further presented herein are nucleic acid molecules encoding the alteredpolymerase enzymes presented herein. For any given altered polymerasewhich is a mutant version of a polymerase for which the amino acid,sequence and preferably also the wild type nucleotide sequence encodingthe polymerase is known, it is possible to obtain a nucleotide sequenceencoding the mutant according to the basic principles of molecularbiology. For example, given that the wild type nucleotide sequenceencoding 9° N polymerase is known, it is possible to deduce a nucleotidesequence encoding any given mutant version of 9° N having one or moreamino acid substitutions using the standard genetic code. Similarly,nucleotide sequences can readily be derived for mutant versions otherpolymerases such as, for example. Vent™, Pfu, Tsp JDF-3, Taq, etc.Nucleic acid molecules having the required nucleotide sequence may thenbe constructed using standard molecular biology techniques known in theart.

In accordance with the embodiments presented herein, a defined nucleicacid includes not only the identical nucleic acid but also any minorbase variations including, in particular, substitutions in cases whichresult in a synonymous codon (a different codon specifying the sameamino acid residue) due to the degenerate code in conservative aminoacid substitutions. The term “nucleic acid sequence” also includes thecomplementary sequence to any single stranded sequence given regardingbase variations.

The nucleic acid molecules described herein may also, advantageously, beincluded in a suitable expression vector to express the polymeraseproteins encoded therefrom in a suitable host. Incorporation of clonedDNA into a suitable expression vector for subsequent transformation ofsaid cell and subsequent selection of the transformed cells is wellknown to those skilled in the art as provided in Sambrook et al. (1989),Molecular cloning: A Laboratory Manual, Cold Spring Harbor Laboratory,which is incorporated by reference in its entirety.

Such an expression vector includes a vector having a nucleic acidaccording to the embodiments presented herein operably linked toregulatory sequences, such as promoter regions, that are capable ofeffecting expression of said DNA fragments. The term “operably linked”refers to a juxtaposition wherein the components described are in arelationship permitting them to function in their intended manner. Suchvectors may be transformed into a suitable host cell to provide for theexpression of a protein according to the embodiments presented herein.

The nucleic acid molecule may encode a mature protein or a proteinhaving a prosequence, including that encoding a leader sequence on thepreprotein which is then cleaved by the host cell to form a matureprotein. The vectors may be, for example, plasmid, virus or phagevectors provided with an origin of replication, and optionally apromoter for the expression of said nucleotide and optionally aregulator of the promoter. The vectors may contain one or moreselectable markers, such as, for example, an antibiotic resistance gene.

Regulatory elements required for expression include promoter sequencesto bind RNA polymerase and to direct an appropriate level oftranscription initiation and also translation initiation sequences forribosome binding. For example, a bacterial expression vector may includea promoter such as the lac promoter and for translation initiation theShine-Dalgamo sequence and the start codon AUG. Similarly, a eukaryoticexpression vector may include a heterologous or homologous promoter forRNA polymerase H, a downstream polyadenylation signal, the start codonAUG, and a termination codon for detachment of the ribosome. Suchvectors may be obtained commercially or be assembled from the sequencesdescribed by methods well known in the art.

Transcription of DNA encoding the polymerase by higher eukaryotes may beoptimised by including an enhancer sequence in the vector. Enhancers arecis-acting elements of DNA that act on a promoter to increase the levelof transcription. Vectors will also generally include origins ofreplication in addition to the selectable markers.

EXAMPLE 1 General Assay Methods and Conditions

The following paragraphs describe general assay conditions used in theExamples presented below.

1. Cloning and Expression of Polymerases

This section describes the approach used for cloning and expression ofthe various polymerase mutants used in the Examples below.

Mutagenesis wax performed on the gene encoding the backbone genesequence for the polymerase using standard site-directed mutagenesismethodology. For each mutation made, proper sequence of the mutatedgenes w as confirmed by sequencing the cloned gene sequence.

The polymerase genes were subcloned into a pET11a vector and transformedinto BL21 Star (DE3) expression cells from Invitrogen. The transformedcells were cultured at 37° C. in 2.8 L. Fernbock flasks until an OD600of 0.8 was reached. Protein expression was then induced by addition of 1mM IPTG, followed by 3 hours of additional growth. The cultures werethen centrifuged at 7000 rpm for 20 minutes. Cell pellets were stored at−20° C. until purification.

Bacterial cell lysis was performed by resuspending the frozen culturesin 10× w/v lysis buffer (Tris pH 7.5, 500 mM NaCl, 1 mM EDTA, 1 mM DTT).EDTA free protease inhibitor (Roche) was added to the resuspended cellpellet. All lysis and purification steps were performed at 4° C. There-suspended culture was passed through a microfluidizer four times tocomplete cell lysis. The lysate was then centrifuged at 20,000 rpm for20 minutes to remove cell debris. Polyethylenimine (final concentration0.5%) was added to the supernatant slowly with stirring for 45 minutesto precipitate bacterial nucleic acid. The lysate was centrifuged at20,000 rpm for 20 minutes: the pellet was discarded. The lysate was thenammonium sulfate precipitated using two volumes of cold saturated(NH4)2SO4 in sterile dH2O. The precipitated protein was centrifuged at20,000 rpm for 20 minutes. The protein pellets were resuspended in 250mL of Buffer A (50 mM Tris pH 7.5, 50 mM KCl, 0.1 mM EDTA, 1 mM DTT).The resuspended lysate was then purified using a 5 mL SP FastFlow column(GE) pro-equilibrated in buffer A. The column was eluted using a 50 mLgradient from 0.1 to 1 M KCl. Peak fractions were pooled, and dilutedwith buffer C (Tris pH 7.5, 0.1 mM EDTA. 1 mM DTT) until theconductivity was equal to buffer D (Tris pH 7.5, 50 mM KCl, 0.1 mM EDTA,1 mM DTT). The pooled fractions were then loaded onto a 5 mL HiTrapHeparin Fastflow column. The polymerase was then eluted using a 1.00 mLgradient from 50 mM to 1 M KCl. Peak fractions were pooled, dialyzedinto storage buffer (20 mM Tris pH 7.5, 300 mM KCl 0.1 mM EDTA, 50%Glycerol) and frozen at −80° C.

2. Phasing/Pre-phasing Analysis

This section describes the approach used for to analyze performance ofthe polymerase mutants used in the Examples below in a sequencing bysynthesis assay.

Sequencing experiments are used to generate phasing and pre-phasingvalues. The experiments are carried out on a MiSeq system (Illumina,Inc., San Diego. Calif.), according to manufacturer instructions. Forexample, for each polymerase, a separate incorporation mixes (IMX) wasgenerated and a 150 cycle run was performed using a different, flowcelllane for each IMX. Standard V3 MiSeq reagent formulations were used,with the standard polymerase substituted with the polymerase beingtested, at a concentration of 30 μg/mL. The standard time for incubationof IMX on the flowcell was shortened to 6 seconds. The DNA library usedwas made following the standard Nextera™ protocol (Illumina, Inc.) usingE. coli genomic DNA. Illumina RTA Software was used to evaluate phasingand pre-phasing levels.

EXAMPLE 2 Identification and Screen of 9° N polymerase Mutants forPhasing/Pre-Phasing

A saturation mutagenesis screen of residues in the 3′ block pocket isperformed. Mutations to modified 9° N polymerase backbone sequence (SEQID NO: 31) are generated, cloned, expressed and purified as describedgenerally in Example 1.

The purified mutant polymerases are screened for phasing/pre-phasingactivity as described above in Example 1. The phasing and pre-phasingactivity of the tested mutants is compared to the control polymerasehaving the sequence set forth in SEQ ID NOS: 31.

Results of the analysis are summarized in the table below. As shown inthe table, each of the above mutants shows unexpected and significantimprovements in one or more of phasing and pre-phasing when compared tothe control polymerases.

SEQ Phasing reduction compared to Mutant ID NO: control? Control 31 —Mutant 1 33 Yes Mutant 2 34 Yes Mutant 3 35 Yes Mutant 4 36 Yes Mutant 537 Yes Mutant 6 38 Yes Mutant 7 39 Yes Mutant 8 40 Yes

EXAMPLE 3 Screen of Mutants of 9° N WT Polymerase

Mutations to a Thermococcus sp. 9° N-7 (9° N ) wild type polymerasebackbone sequence (SEQ ID NO: 10) are generated, cloned, expressed andpurified as described generally in Example 1, producing polymeraseenzymes having the amino acid sequences set forth as SEQ ID NOs: 11-12,as described in the table below.

The purified mutant polymerases are screened for phasing/pre-phasingactivity as generally described above in Example 1 and compared to thecontrol polymerase having the sequence set forth in SEQ ID NO: 10. Thosepolymerases having the following mutations are shown to have improvedphasing and/or pre-phasing activity compared to the control:

Mutant SEQ ID NO: T144A 11 T144G 11 T144L 11 G153D 11 K476W 11 L478S 11L478R 11 L478T 11 T590I 11 T590G 11 A639V 11 A639F 11 D718N 11 T144A 11G153D K476W L478S T590I A639V D718N T144A 11 G153D T590I A639V D718NK476W 11 L478S T590I K476W 11 T590I T144A 12 L408A Y409A P410I G153D 12L408A Y409A P410I K476W 12 L408A Y409A P410I L478S 12 L408A Y409A P410IT590I 12 L408A Y409A P410I A639V 12 L408A Y409A P410I D718N 12 L408AY409A P410I T144A 12 G153D K476W L478S T590I A639V D718N L408A Y409AP410I T144A 12 G153D T590I A639V D718N L408A Y409A P410I K476W 12 L478ST590I L408A Y409A P410I K476W 12 T590I L408A Y409A P410I T144A 12 L408AY409A P410I A485V G153D 12 L408A Y409A P410I A485V K476W 12 L408A Y409AP410I A485V L478S 12 L408A Y409A P410I A485V T590I 12 L408A Y409A P410IA485V A639V 12 L408A Y409A P410I A485V D718N 12 L408A Y409A P410I A485VT144A 12 G153D K476W L478S T590I A639V D718N L408A Y409A P410I A485VT144A 12 G153D T590I A639V D718N L408A Y409A P410I A485V K476W 12 L478ST590I L408A Y409A P410I A485V K476W 12 T590I L408A Y409A P410I A485V

EXAMPLE 4 Screen of Mutants of 9° N Exo⁻ Polymerase

Mutations to Exo⁻ polymerase backbone sequence (SEQ ID NO: 13) aregenerated, cloned, expressed and purified as described generally inExample 1, producing polymerase enzymes having the ammo acid sequencesset forth as SEQ ID NOS: 14-15.

The purified mutant polymerases are screened tor phasing/pre-phusingactivity as generally described above in Example 1 and compared to thecontrol polymerase having the sequence set forth in SEQ ID NO: 13. Thosepolymerases having the following mutations are shown to have improvedphasing and/or pre-phasing activity compared to the control:

Mutant SEQ ID NO: T144A 14 G153D 14 K476W 14 L478S 14 T590I 14 A639V 14D718N 14 T144A 14 G153D K476W L478S T590I A639V D718N T144A 14 G153DT590I A639V D718N K476W 14 L478S T590I K476W 14 T590I T144A 15 L408AY409A P410I G153D 15 L408A Y409A P410I K476W 15 L408A Y409A P410I L478S15 L408A Y409A P410I T590I 15 L408A Y409A P410I A639V 15 L408A Y409AP410I D718N 15 L408A Y409A P410I T144A 15 G153D K476W L478S T590I A639VD718N L408A Y409A P410I T144A 15 G153D T590I A639V D718N L408A Y409AP410I K476W 15 L478S T590I L408A Y409A P410I K476W 15 T590I L408A Y409AP410I T144A 15 L408A Y409A P410I A485V G153D 15 L408A Y409A P410I A485VK476W 15 L408A Y409A P410I A485V L478S 15 L408A Y409A P410I A485V T590I15 L408A Y409A P410I A485V A639V 15 L408A Y409A P410I A485V D718N 15L408A Y409A P410I A485V T144A 15 G153D K476W L478S T590I A639V D718NL408A Y409A P410I A485V T144A 15 G153D T590I A639V D718N L408A Y409AP410I A485V K476W 15 L478S T590I L408A Y409A P410I A485V K476W 15 T590IL408A Y409A P410I A485V

EXAMPLE 5 Screen of Mutants of Altered 9° N Polymerase

Mutations to an altered 9° N polymerase backbone sequence (backboneselected from SEQ ID NO: 16, 27, 29 and 31) are generated, cloned,expressed and purified as described generally in Example 1, producingpolymerase enzymes having the amino acid sequences set forth, as SEQ IDNOs: 17,28, 30 and 32-40.

The purified mutant polymerases are screened for phasing/pre-phasingactivity as generally described above in Example 1 and compared to thecontrol polymerases having the sequence set forth in SEQ ID NO: 16, 27,29 and 31. Those polymerases having the following mutations are shown tohave improved phasing and/or pre-phasing activity compared to thecontrol:

Mutant SEQ ID NOs: T144A 17, 28, 30, 32 G153D 17, 28, 30, 32 K476W 17,28, 30, 32, 35 L478S 17, 28, 30, 32, 36 T590I 17, 28, 30, 32, 39 A639V17, 28, 30, 32 D718N 17, 28, 30, 32 T144A 17, 28, 30, 32, 33, 34 G153DK476W L478S T590I A639V D718N T144A 17, 28, 30, 32 G153D T590I A639VD718N K476W 17, 28, 30, 32, 37 L478S T590I K476W 17, 28, 30, 32, 38T590I K476W 17, 28, 30, 32, 40 L478S

EXAMPLE 6 Screen of Mutants of Pfu Exo⁻ Polymerase

Based upon analysis of sequence alignment to the 9° N polymerasebackbone sequence (sec FIG. 1), specific mutations to Pyrococcusfuriosus (Pfu) Exo⁻ polymerase backbone sequence (SEQ ID NO: 18) aregenerated, clotted, expressed and purified as described generally inExample h producing polymerase enzymes having the amino acid sequencesset forth as SEQ ID NOs: 19-20.

The purified mutant polymerases are screened for phasing/pre-phasingactivity as generally described above in Example 1 and compared to thecontrol polymerase having the sequence set forth in SEQ ID NO: 18. Thosepolymerases having the following mutations are shown to have improvedphasing and/or pre-phasing activity compared to the control:

Mutant SEQ ID NO: T144A 19 G153D 19 K477W 19 L479S 19 T591I 19 A640V 19D719N 19 T144A 19 G153D K477W L479S T591I A640V D719N T144A 19 G153DT591I A640V D719N K477W 19 L479S T591I K477W 19 T591I 19 T144A 20 L409AY410A P411I G153D 20 L409A Y410A P411I K477W 20 L409A Y410A P411I L479S20 L409A Y410A P411I T591I 20 L409A Y410A P411I A640V 20 L409A Y410AP411I D719N 20 L409A Y410A P411I T144A 20 G153D K477W L479S T591I A640VD719N L409A Y410A P411I T144A 20 G153D T591I A640V D719N L409A Y410AP411I K477W 20 L479S T591I L409A Y410A P411I K477W 20 T591I L409A Y410AP411I

EXAMPLE 7 Screen of Mutants of KOD1 Exo⁻ Polymerase

Based upon analysis of sequence alignment to the 9° N polymerasebackbone sequence (sec FIG. 1), specific mutations to Thermococcuskodakaraenis (KOD1) Exo⁻ polymerase backbone sequence (SEQ ID NO: 21)are generated, cloned, expressed and purified as described generally inExample 1, producing polymerase enzymes having the amino acid sequencesset forth as SEQ ID NOs: 22-23.

The purified mutant polymerases are screened for phasing/pre-phasingactivity as generally described above in Example 1 and compared to thecontrol polymerase having the sequence set forth in SEQ ID NO: 21. Thosepolymerases having the following mutations are shown to have improvedphasing and/or pre-phasing activity compared to the control:

Mutant SEQ ID NO: T144A 22 G153D 22 K476W 22 L478S 22 T590I 22 A639V 22D718N 22 T144A 22 G153D K476W L478S T590I A639V D718N T144A 22 G153DT590I A639V D718N K476W 22 L478S T590I K476W 22 T590I T144A 23 L408AY409A P410I G153D 23 L408A Y409A P410I K476W 23 L408A Y409A P410I L478S23 L408A Y409A P410I T590I 23 L408A Y409A P410I A639V 23 L408A Y409AP410I D718N 23 L408A Y409A P410I T144A 23 G153D K476W L478S T590I A639VD718N L408A Y409A P410I T144A 23 G153D T590I A639V D718N L408A Y409AP410I K476W 23 L478S T590I L408A Y409A P410I K476W 23 T590I L408A Y409AP410I

EXAMPLE 8 Screen of Mutants of MMS2 Exo⁻ Polymerase

Based upon analysis of sequence alignment to the 9° N polymerasebackbone sequence (sec FIG. 1), specific mutations to Methanococcusmaripaludis (MMS2) Exo⁻ polymerase backbone sequence (SEQ ID NO: 24) areidentified based upon homology in an alignment with 9° N polymerase (seeFIG. 2). The mutants are generated, cloned, expressed and purified asdescribed generally in Example 1, producing polymerase enzymes havingthe amino acid sequences set forth as SEQ ID NOS: 25-26.

The purified mutant polymerases are screened for phasing/pre-phasingactivity as generally described above in Example 1 and compared to thecontrol polymerase having the sequence set forth in SEQ ID NO: 24. Thosepolymerases having the following mutations are shown to have improvedphasing and/or pre-phasing activity compared to the control:

Mutant SEQ ID NO: V156A 25 K165D 25 Y492W 25 I494S 25 T609I 25 A658V 25V156A 25 G153D Y492W I494S T609I A658V V156A 25 G153D T609I A658V Y492W25 I494S T609I Y492W 25 T609I V156A 26 L417A Y418A P419I G153D 26 L417AY418A P419I Y492W 26 L417A Y418A P419I I494S 26 L417A Y418A P419I T609I26 L417A Y418A P419I A658V 26 L417A Y418A P419I V156A 26 G153D Y492WI494S T609I A658V L417A Y418A P419I V156A 26 G153D T609I A658V L417AY418A P419I Y492W 26 I494S T609I L417A Y418A P419I Y492W 26 T609I L417AY418A P419I

Throughout this application various publications, patents and/or patentapplications have been referenced. The disclosure of these publicationsin their entireties is hereby incorporated by reference in thisapplication.

The term comprising is intended herein to be open-ended, including notonly the recited elements, but further encompassing any additionalelements.

A number of embodiments have been described. Nevertheless, it will beunderstood that various modifications may be made. Accordingly, otherembodiments are within the scope of the following claims.

1. A recombinant DNA polymerase comprising an amino acid sequence thatis at least 60%, 70%, 80%, 90%, 95%, 99% identical to SEQ ID NO: 10,which recombinant DNA polymerase comprises at least one amino acidsubstitution mutation at one or more positions functionally equivalentto Thr144, Gly153, Lys476, Leu478, Thr590, Ala639 or Asp718 in the 9° NDNA polymerase amino acid sequence.
 2. The altered polymerase of claim1, wherein said substitution mutation at position Thr144 comprises amutation to a nonpolar amino acid.
 3. The altered polymerase of claim 1,wherein said substitution mutation at position Thr144 comprises amutation homologous to Thr144Ala, Thr144Gly, or Thr144Leu.
 4. Thealtered polymerase of claim 1, wherein said substitution mutation atposition Gly153 comprises a mutation to a polar amino acid.
 5. Thealtered polymerase of claim 1, wherein said substitution mutation atposition Gly153 comprises a mutation homologous to Gly153Asp.
 6. Thealtered polymerase of claim 1, wherein said substitution mutation atposition Lys476 comprises a mutation to a hydrophobic amino acid.
 7. Thealtered polymerase of claim 1, wherein said substitution mutation atposition Lys476 comprises a mutation homologous to Lys476Trp.
 8. Thealtered polymerase of claim 1, wherein said substitution mutation atposition Leu478 comprises a mutation to a polar amino acid.
 9. Thealtered polymerase of claim 1, wherein said substitution mutation atposition Leu478 comprises a mutation homologous to Leu478Ser, Leu478Arg,or Leu478Thr.
 10. The altered polymerase of claim 1, wherein saidsubstitution mutation at position Thr590 comprises a mutation to anon-polar amino acid.
 11. The altered polymerase of claim 1, whereinsaid substitution mutation at position Thr590 comprises a mutationhomologous to Thr590Ile, or Thr590Gly.
 12. The altered polymerase ofclaim 1, wherein said substitution mutation at position Ala639 comprisesa mutation homologous to Ala639Val, or Ala639Phe.
 13. The alteredpolymerase of claim 1, wherein said substitution mutation at positionAsp718 comprises a mutation to an uncharged amino acid.
 14. The alteredpolymerase of claim 1, wherein said substitution mutation at positionAsp718 comprises a mutation homologous to Asp718Asn.
 15. The alteredpolymerase of claim 1, wherein the polymerase is a DNA polymerase. 16.The altered polymerase of claim 1, wherein the DNA polymerase is afamily B type DNA polymerase.
 17. The altered polymerase of claim 16which is selected from the group consisting of a family B archael DNApolymerase, human DNA polymerase-α, T4, RB69, and phi29 phage DNApolymerase.
 18. The altered polymerase of claim 17, wherein the family Barchael DNA polymerase is from a genus selected from the groupconsisting of Thermococcus Pyrococcus, and Methanococcus.
 19. The familyB archael DNA polymerase of claim 17 which is selected from the groupconsisting of Vent, Deep Vent, 9° N, and Pfu polymerase.
 20. The alteredpolymerase of claim 19, wherein the family B archael DNA polymerase is9° N polymerase. 21-85. (canceled)